Anti-PD-1 antibodies / PD-1 inhibitors & Gut microbiota

In cancer patients, the presence of

• Bifidobacterium breve


• Bifidobacterium longum


• Akkermansia muciniphila


• Faecalibacterium prausnitzii
  in the gastrointestinal tracts may enhance the immune response to Anti-PD-1 antibodies / PD-1 inhibitors and potentially lead to prolonged survival.

Miller & Carson 2020 Gut Pathog 12: 43

see also:
Akkermansia muciniphila & Anti-PD-1 antibodies / PD-1 inhibitors
Akkermansia muciniphila & Immune Checkpoint Inhibitors (ICIs)
Anti-CTLA-4 / CTLA-4 antibodies & Gut microbiota
Faecalibacterium prausnitzii & Immune Checkpoint Inhibitors (ICIs)
Gut microbiota & Immune Checkpoint Inhibitors (ICIs)